PL3645002T3 - Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca - Google Patents

Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca

Info

Publication number
PL3645002T3
PL3645002T3 PL18745732.0T PL18745732T PL3645002T3 PL 3645002 T3 PL3645002 T3 PL 3645002T3 PL 18745732 T PL18745732 T PL 18745732T PL 3645002 T3 PL3645002 T3 PL 3645002T3
Authority
PL
Poland
Prior art keywords
activators
treatment
methods
heart failure
cardiac sarcomere
Prior art date
Application number
PL18745732.0T
Other languages
English (en)
Inventor
Narimon HONARPOUR
Fady Malik
Original Assignee
Amgen Inc.
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc., Cytokinetics, Inc. filed Critical Amgen Inc.
Publication of PL3645002T3 publication Critical patent/PL3645002T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18745732.0T 2017-06-30 2018-06-29 Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca PL3645002T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Publications (1)

Publication Number Publication Date
PL3645002T3 true PL3645002T3 (pl) 2025-03-24

Family

ID=63013097

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18745732.0T PL3645002T3 (pl) 2017-06-30 2018-06-29 Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca

Country Status (22)

Country Link
US (4) US11576910B2 (pl)
EP (2) EP3645002B1 (pl)
JP (3) JP2020526483A (pl)
CN (1) CN110996953A (pl)
AU (2) AU2018290983B2 (pl)
BR (1) BR112019028046A2 (pl)
CA (1) CA3068588A1 (pl)
DK (1) DK3645002T3 (pl)
ES (1) ES3008457T3 (pl)
FI (1) FI3645002T3 (pl)
HR (1) HRP20241729T1 (pl)
HU (1) HUE069805T2 (pl)
LT (1) LT3645002T (pl)
MA (1) MA49508B1 (pl)
MD (1) MD3645002T2 (pl)
MX (2) MX2020000190A (pl)
PL (1) PL3645002T3 (pl)
PT (1) PT3645002T (pl)
RS (1) RS66581B1 (pl)
SI (1) SI3645002T1 (pl)
SM (1) SMT202500067T1 (pl)
WO (1) WO2019006235A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102474467B1 (ko) 2013-03-14 2022-12-05 암젠 인크 복소환식 화합물 및 그들의 용도
WO2019006235A1 (en) * 2017-06-30 2019-01-03 Amgen Inc. METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS
TWI769272B (zh) 2017-06-30 2022-07-01 美商安進公司 奧美卡替莫卡必爾的合成
EP3594199B1 (en) 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
PE20220426A1 (es) * 2019-05-19 2022-03-29 Myokardia Inc Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida
WO2021163172A1 (en) * 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
BR112022025551A2 (pt) * 2020-06-15 2023-03-07 Myokardia Inc Tratamento de disfunção atrial
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
SI4243825T1 (sl) 2020-11-12 2026-01-30 Amgen Inc. Omekamtiv mekarbil za zdravljenje srčnega popuščanja pri izbranih skupinah bolnikov
US11702380B2 (en) 2021-03-10 2023-07-18 Amgen Inc. Synthesis of omecamtiv mecarbil
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
IL319671A (en) 2022-09-26 2025-05-01 Edgewise Therapeutics Inc 4,1-Dihydroquinazolinone compounds and their uses
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
CN121194963A (zh) 2023-03-27 2025-12-23 艾知怀斯治疗学公司 喹啉酮酰胺类化合物及其用途
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
CA2320193A1 (en) 1998-02-10 1999-08-19 Welfide Corporation Controlled release preparation
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
MXPA06014495A (es) 2004-06-17 2007-03-01 Cytokinetics Inc Compuestos, composiciones y metodos.
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
MX2008014418A (es) 2006-05-15 2008-11-27 Wisconsin Alumni Res Found Administracion pulmonar de la 1 alfa, 25-dihidroxivitamina d3 y co-administracion de la homona paratiroidea o calcitonina.
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
BRPI0810140A2 (pt) 2007-04-19 2014-10-29 Dong A Pharm Co Ltd Composição de microempresa biodegradável adequada para a liberação controlada de um peptídeo de controle de glicose e formulação da mesma
KR102474467B1 (ko) 2013-03-14 2022-12-05 암젠 인크 복소환식 화합물 및 그들의 용도
CA2902424A1 (en) * 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
AU2018214629A1 (en) 2017-02-06 2019-08-22 Acceleron Pharma Inc. Compositions and methods for treating heart failure
WO2019006235A1 (en) 2017-06-30 2019-01-03 Amgen Inc. METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS
TWI769272B (zh) 2017-06-30 2022-07-01 美商安進公司 奧美卡替莫卡必爾的合成
EP3594199B1 (en) 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
EP3599243B1 (en) 2018-07-26 2023-04-12 CVIE Therapeutics Limited 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
JP7560134B2 (ja) 2019-03-05 2024-10-02 ウインドトゥリー・セラピューティクス・インコーポレイテッド 急性心不全（ａｈｆ）の治療のためのイスタロキシム含有静脈用製剤
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041198A4 (en) 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021092598A1 (en) 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
WO2021136477A1 (zh) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
WO2021163172A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
SI4243825T1 (sl) 2020-11-12 2026-01-30 Amgen Inc. Omekamtiv mekarbil za zdravljenje srčnega popuščanja pri izbranih skupinah bolnikov
US11702380B2 (en) 2021-03-10 2023-07-18 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
HRP20241729T1 (hr) 2025-03-14
US11576910B2 (en) 2023-02-14
MX2020000190A (es) 2020-07-22
AU2018290983B2 (en) 2023-11-23
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
LT3645002T (lt) 2025-02-10
FI3645002T3 (fi) 2025-01-29
US20250255862A1 (en) 2025-08-14
EP4512470A3 (en) 2025-04-23
CN110996953A (zh) 2020-04-10
AU2024200991B2 (en) 2025-04-10
US11931358B2 (en) 2024-03-19
EP3645002A1 (en) 2020-05-06
AU2024200991A1 (en) 2024-03-07
RS66581B1 (sr) 2025-04-30
JP2023088944A (ja) 2023-06-27
MD3645002T2 (ro) 2025-04-30
PT3645002T (pt) 2025-01-24
SI3645002T1 (sl) 2025-03-31
WO2019006235A1 (en) 2019-01-03
SMT202500067T1 (it) 2025-03-12
US20230355615A1 (en) 2023-11-09
US12295952B2 (en) 2025-05-13
MA49508A (fr) 2020-05-06
EP4512470A2 (en) 2025-02-26
MA49508B1 (fr) 2024-12-31
CA3068588A1 (en) 2019-01-03
ES3008457T3 (en) 2025-03-24
US20200155547A1 (en) 2020-05-21
JP2025165979A (ja) 2025-11-05
EP3645002B1 (en) 2024-10-30
US20230149394A1 (en) 2023-05-18
DK3645002T3 (da) 2024-12-16
HUE069805T2 (hu) 2025-04-28
JP2020526483A (ja) 2020-08-31
MX2022015115A (es) 2023-01-18

Similar Documents

Publication Publication Date Title
PL3645002T3 (pl) Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca
EP4230133C0 (en) CONTROLLED AND PRECISE TREATMENT OF CARDIAC TISSUES
IL272300A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
EP3614943A4 (en) IMPROVED ELECTROPORATION OF HEART TISSUE
IL253954A0 (en) Implantable devices and related methods for heart failure monitoring
IL253351A0 (en) Cardiac stimulation of conduction pathways between the atria and ventricles and of tissues associated with these pathways
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
PL3402888T3 (pl) Środki i sposoby leczenia hbv
PL3265053T3 (pl) Sposoby leczenia skóry
IL247088A0 (en) Matching and tracking time sequences of heart activation
EP3503904C0 (en) ASCAROSIDE TREATMENT OF EOSINOPHIL ESOPHAGITIS
EP3724219A4 (en) TREATMENT OF FIBROSIS BY GENETICALLY MODIFIED MACROPHAGES
HUE041700T2 (hu) Hosszú, nem kódoló RNS-ek (IncRNS-ek) szívhipertrófia terápiájára és diagnosztizálására
EP3266380C0 (en) DETERMINATION OF TISSUE THICKNESS
EP3424557A4 (en) INTRAKARDIAL DEFIBRILLATION CATHETER
EP3436569A4 (en) ADVANCED DIRECT CARDIAL PROGRAMMING
EP3609500A4 (en) ADIPOCYTE TREATMENT
EP3576790A4 (en) TREATMENT OF DIURETIC RESISTANCE
EP3478822C0 (en) Preservation of microorganisms
EP3681505C0 (en) IMPROVED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT
IL270900A (en) Treatment of cutaneous disorders
EP3066077A4 (en) Treatment of cardiac remodeling and other heart conditions
ES2894844T8 (es) Tratamiento de la calcificación vascular
EP3535318C0 (en) USE OF SUCCINIC ANHYDRIDE MONOSUBSTITUTE
EP3210575C0 (en) CARDIAC IMPLANT